Talis Biomedical Corporation
TLIS
$1.60
-$0.08-4.76%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -94.01% | -24.12% | -82.41% | 1.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -94.01% | -24.12% | -82.41% | 1.57% |
| Cost of Revenue | -84.84% | -81.62% | -54.20% | -55.71% | -43.42% |
| Gross Profit | 83.96% | 80.43% | 54.65% | 54.52% | 44.84% |
| SG&A Expenses | 24.45% | 4.39% | -8.34% | -0.25% | -30.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.57% | -54.40% | -40.87% | -37.96% | -39.05% |
| Operating Income | 41.57% | 51.86% | 41.04% | 36.64% | 39.90% |
| Income Before Tax | 41.14% | 26.90% | 50.02% | 39.73% | 44.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 41.14% | 26.90% | 50.02% | 39.73% | 44.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 41.14% | 26.90% | 50.02% | 39.73% | 44.34% |
| EBIT | 41.57% | 51.86% | 41.04% | 36.64% | 39.90% |
| EBITDA | 41.48% | 52.80% | 32.03% | 26.71% | 38.30% |
| EPS Basic | 41.31% | 27.27% | 50.28% | 40.32% | 44.88% |
| Normalized Basic EPS | 41.31% | 55.01% | 42.63% | 40.32% | 44.88% |
| EPS Diluted | 41.31% | 27.27% | 50.28% | 40.32% | 44.88% |
| Normalized Diluted EPS | 41.31% | 55.01% | 42.63% | 40.32% | 44.88% |
| Average Basic Shares Outstanding | 0.28% | 0.52% | 0.54% | 0.98% | 0.98% |
| Average Diluted Shares Outstanding | 0.28% | 0.52% | 0.54% | 0.98% | 0.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
